Impact of unsolicited reporting notifications on providers' prescribing behavior: An experimental study on Maryland PDMP data.

Inappropriate opioid prescription Opioid overdose Prescription Drug Monitoring Programs Prescription drug abuse Unsolicited reporting notification

Journal

Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587

Informations de publication

Date de publication:
01 Jul 2023
Historique:
received: 07 10 2022
revised: 19 04 2023
accepted: 21 04 2023
medline: 19 6 2023
pubmed: 11 5 2023
entrez: 10 5 2023
Statut: ppublish

Résumé

Unsolicited Reporting Notifications(URNs) have been a component of Maryland's Prescription Drug Monitoring Program (PDMP) since 2016. We evaluated the effect of URNs on providers' prescription behaviors. This is a quasi-experimental study of providers who were issued at least one URN from January 2018 to April 2021. Providers for whom URNs were not successfully delivered were designated as a comparison group. The outcome variables were average daily opioid and benzodiazepine prescriptions, average morphine milligram equivalents per patient, and proportion of overlapping opioid and benzodiazepine, either with or without muscle relaxant prescriptions. Changes were compared before versus after the issuance of a URN among the intervention and comparison groups using "Generalized Estimation Equation" and "Generalized Linear" Models. We also conducted stratified analyses by types of URN, including notifications for multiple provider episodes (MPE), overdose fatality (ODF), and dangerous drug combinations (DDC). The average daily number of opioids prescriptions (3.3% decrease in the intervention group vs 22.7% increase in the comparison group, P<0.001), co-prescription of opioids and benzodiazepines either with muscle relaxants (68.0% decrease vs. 36.1% decrease, P<0.001), or without muscle relaxants (6.0% decrease vs. 16.3% increase, P<0.001), significantly reduced after the first URN regardless of the type of URN. Stratified analysis by types of URNs showed that ODF and DDC URNs had a significant effect on most of the outcomes of interest. The findings suggest that unsolicited reporting, especially particular types of URNs including ODF and DDC, is associated with subsequent changes in unsafe prescribing behaviors.

Sections du résumé

BACKGROUND BACKGROUND
Unsolicited Reporting Notifications(URNs) have been a component of Maryland's Prescription Drug Monitoring Program (PDMP) since 2016. We evaluated the effect of URNs on providers' prescription behaviors.
METHODS METHODS
This is a quasi-experimental study of providers who were issued at least one URN from January 2018 to April 2021. Providers for whom URNs were not successfully delivered were designated as a comparison group. The outcome variables were average daily opioid and benzodiazepine prescriptions, average morphine milligram equivalents per patient, and proportion of overlapping opioid and benzodiazepine, either with or without muscle relaxant prescriptions. Changes were compared before versus after the issuance of a URN among the intervention and comparison groups using "Generalized Estimation Equation" and "Generalized Linear" Models. We also conducted stratified analyses by types of URN, including notifications for multiple provider episodes (MPE), overdose fatality (ODF), and dangerous drug combinations (DDC).
RESULTS RESULTS
The average daily number of opioids prescriptions (3.3% decrease in the intervention group vs 22.7% increase in the comparison group, P<0.001), co-prescription of opioids and benzodiazepines either with muscle relaxants (68.0% decrease vs. 36.1% decrease, P<0.001), or without muscle relaxants (6.0% decrease vs. 16.3% increase, P<0.001), significantly reduced after the first URN regardless of the type of URN. Stratified analysis by types of URNs showed that ODF and DDC URNs had a significant effect on most of the outcomes of interest.
CONCLUSION CONCLUSIONS
The findings suggest that unsolicited reporting, especially particular types of URNs including ODF and DDC, is associated with subsequent changes in unsafe prescribing behaviors.

Identifiants

pubmed: 37163865
pii: S0376-8716(23)00134-5
doi: 10.1016/j.drugalcdep.2023.109896
pii:
doi:

Substances chimiques

Analgesics, Opioid 0
RV 538 73257-80-4
Benzodiazepines 12794-10-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109896

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Anna Gribble was the Provider Engagement and Policy Manager with the Maryland Department of Health (MDH) at the time of data analysis and drafting the report. She worked in the Office of Provider Engagement and Regulation (OPER) and she was responsible for PDMP programmatic activities and policies. Lindsey Goddard is an Epidemiologist. She also works in the Office of Provider Engagement and Regulation (OPER) and she is responsible for data analysis and management for the PDMP. Her staff time is supported by the Maryland Overdose Data to Action Cooperative Agreement from CDC and FY 2020 Harold Rogers Grant, DOJ, BJA. All other authors have no competing interest to declare.

Auteurs

Masoumeh Amin-Esmaeili (M)

Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, United States. Electronic address: mamines1@jhu.edu.

Rachel Alinsky (R)

Department of Pediatrics, Johns Hopkins University School of Medicine, United States; Department of Population, Family, and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, United States.

Renee M Johnson (RM)

Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, United States.

Anna Gribble (A)

Maryland Department of Health (MDH), Office of Provider Engagement and Regulation (OPER), United States.

Natasha Oyedele (N)

Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, United States.

Taylor Parnham (T)

Department of Health Behavior and Society, Bloomberg School of Public Health, Johns Hopkins University, United States.

Lindsey Goddard (L)

Maryland Department of Health (MDH), Office of Provider Engagement and Regulation (OPER), United States.

Ryoko Susukida (R)

Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH